Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others.
As obesity prevalence rises, there is evidence that fatty liver disease can act synergistically with other chronic liver diseases to aggravate parenchymal injury. This is characterized best in chronic hepatitis C, where steatosis is caused by viral and metabolic effects. There is evidence that steatosis and its metabolic abnormalities also exacerbate other diseases, such as alcoholic liver disease, hemochromatosis, and, possibly, drug-induced liver disease. The pathogenesis seems related to increased susceptibility of steatotic hepatocytes to apoptosis, enhanced oxidative injury, and altered hepatocytic regeneration. Data suggest that active management of obesity may improve liver injury and decrease the progression of fibrosis in patients who have other chronic liver diseases.
Clouston
Andrew D
AD
School of Medicine, Southern Division, The University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Jonsson
Julie R
JR
Powell
Elizabeth E
EE
D005234:Fatty Liver / Q000150:complications* / Q000503:physiopathology*; D006432:Hemochromatosis / Q000209:etiology*; D006526:Hepatitis C / Q000209:etiology*; D006801:Humans; D008108:Liver Diseases, Alcoholic / Q000209:etiology*; D009765:Obesity / Q000150:complications; D012307:Risk Factors